San Diego, CA -- (SBWIRE) -- 12/18/2013 -- An investigation on behalf of investors of Targacept , Inc. (NASDAQ:TRGT) shares over potential securities laws violations by Targacept and certain of its directors and officers in connection certain financial statements was announced .

If you purchased shares of Targacept , Inc. (NASDAQ:TRGT), you have certain options and you should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Targacept , Inc. (NASDAQ:TRGT) concerning whether a series of statements by Targacept ,. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Targacept , Inc. reported that its annual Total Revenue declined from $97.64 million in 2011 to $57.86 million in 2012 while its Net Loss decreased from $8.53 million in 2011 to $7.00 million in 2012.

Shares of Targacept , Inc. grew from under $ in late 2012 to as high as $6.08 per share on December 16, 2013.

Then on December 16, 2013, Targacept , Inc. announced negative Top-Line Results from Phase 2b Clinical Trial of TC-5619 in Schizophrenia.

Shares of Targacept , Inc. dropped on December 17, 2013, to as low as $3.91 per share.

Those who purchased shares of Targacept , Inc. (NASDAQ:TRGT), have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Jacob Rosenfeld
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com